FDA clears autoinjector version of UCB’s Zilbrysq for myasthenia gravis
UCB announced that the U.S. Food and Drug Administration has authorized a new autoinjector for Zilbrysq, the company’s daily treatment for generalized myasthenia gravis. The device will provide a second self‑injection option alongside the existing prefilled syringe and is slated to reach U.S. pharmacies in the first quarter of 2027. Approval was based on three small studies that showed the autoinjector delivers the drug reliably and can be used by most participants without prior training.
Why it matters
The new delivery format may make daily dosing easier for patients with limited hand strength, potentially expanding the drug’s market reach. The approval does not alter the drug’s safety profile or eligibility criteria, so prescribing practices and the existing REMS program remain unchanged.
Key facts
- 1The FDA approved an autoinjector for Zilbrysq on October 16, 2026. investing.com
- 2UCB expects the autoinjector to be commercially available in the first quarter of 2027. medicaldaily.com
- 3A Phase 1 crossover study with 14 healthy volunteers demonstrated bioequivalence between the autoinjector and the prefilled syringe. investing.com
- 4In a Phase 3b study of 31 adult patients, 99.8% of 449 autoinjector uses delivered a complete dose. investing.com
- 5A human‑factors usability study showed that 90% of 100 participants successfully performed an injection on their first attempt without training. medicaldaily.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.